Basal cell carcinoma is the most common ofthe cutaneous mal ignancies, accounting for 65 to 75 % of all skin cancers. The natural history ofthis disease is one ofchronic local invasion. Metastatic basal cell carcinoma is a rare clinical entity, with a reported incidence ofonly 0.002 8 to 0.5%. Approximately 85 % of all metastat ic basal cell carcinomas arise in the head and neck region. We p resent a case ofbasal cell carcinoma that spread to the parotid gland in a man who had multiple lesions on his scalp and f ace. We also review the literature on metastatic basal cell carcinoma of the head and neck, and we discuss its epidemiology, etiology, histopath ology, and treatment.
Introduction
Eighty-five percent of metastatic basal cell carcinomas arise in the head and neck region.I The natur al histor y of this disease is one of chronic local invasion of surrounding tissue. However, in rare instances, these tumo rs do metastasize . The first reported case of metastatic basal cell carc inoma was publi shed by Beadles in 1894 . 2 Since then, approximately 200 cases have been documented in small series and case reports.
Three specifi c criteria for a diagnosis of meta stat ic basal cell carcinoma were developed in 1951 .by Lattes and Kessler.' According to these criteria, the primary tum or must arise from the skin and not the muco sa; the histopathology of the primary tum or and that of the metastasis must be identical ; and the metastasis must occur at a site distant from the primary tumor with out evidence of direct extension. Unfo rtun ately, we know that varying histologic pattern s can occur within the same lesion , which makes it difficult to trace a metastasis to a specific prim ary tumo r. Thi s is especially difficult in a patient who has mult iple primary lesions.
In this articl e, we describe the case of a patient who had multiple, recurrent basal cell carcinomas on the scalp and face that metastasized to the parotid gland and periparotid lymph node. We also review the literature on metastatic basal cell carcinoma of the head and nec k, and we discuss its histopathology and therapeutic modal ities.
Case report
Our patient was a 68-year-old white man who had a history of multipl e basal cell carci nomas involving his scalp, face, trunk , and extremities . He was referred to our institution' s Dep artment of Dermatology by his dermatolo gist for Mohs' micrographic surge ry on the recurrent basal cell carcinom as of the right temporal region and the right nasal alar crease. Histologic examinati on revealed that the carcinoma in the right temp oral reg ion was of the nodul ar subtype (figure I) and the lesion in the alar crease was of the infiltrative subtype (figure 2). Prior to his referral to us, the patient had received numerous treatment s for his temple and nasal lesion s over a 10-to 12year period . The se treatme nts included local excisi on , curettage, and electrodesiccation, but no radiation therap y.
Moh s' surgery was first performed on a 0.8-cm recurrent basal cell carcinoma of the right temple in March 1992. A second Mohs' procedur e was performed in that area in May 1993. At that time, the pathology showed a nodul ar pattern that did not extend to the level of muscle. In December 1994, a third Mohs' procedure was required in the same area. Thi s time the pathology showed large tumor nests (a nodular pattern ) with angulated margin s.
Tu mor was found deep to muscle (figure 3). Clear margins were obtained. The right nasa l alar lesion recurred in May 1993 and again in December 1998. On both occasions, the lesio n was treated with Mohs' surgery. There was no evidence of recurrence at the time of this publication.
In May 1997, a palpable 2-cm mass in the region of the right tail of the parotid gland and a new 0.2-cm lesion on the left ear were noted by the patient' s dermatologist. The patient was subsequently referred to our Otolaryngology-Head and Neck Surgery clinic for evaluation of the parotid mass . Cyto logy obtained by fine-needle aspiration of the parotid mass was consistent with metas tatic basal cell carcinoma. On magnetic resonance imaging, the paro tid lesion measured 1.3 x 0.9 em. The patient subsequent ly underwent a right superfic ial parotidectomy with facial nerve dissection, a right selective neck dissectio n enco mpassi ng zones two and three, and a wide local excis ion of the ear lesion. Pathologic examinatio n of the parotid revealed a metastatic basal cell carcinom a with prom inent perineural invasion (figure 4). The histology agai n showe d large tumor nests with angulated margins . Although no normal intraparotid lymph nodes were iden tified , metastasis to and obliteration of an intraparotid lymph node could not be exc luded. The resect ion margins and all 19 lymph nodes were free of malignancy. The ear lesion was also doc umented to be an infiltrative basa l cell carcinoma. A total of 6,000 cGy of external -beam radiation therapy was administered to the right parotid and 4,500 cGy to the right neck. The left ear lesion was widel y excised at the time of the parotidectomy. The final pathology revea led a basal cell carcinoma with clear margins . At the time of this publication, there was no evidence of tumor recurrence.
It seems mos t like ly that the metastatic disease to the parot id spread from the primary tumor that recurre d on the temple in 1994. Th e primary tumor had an unusually deep infiltration, and its histology (figure 5) was very similar to that of the metastasis (figure 6). 
Discussion
In cidence. Metastatic basal cell carcinoma is a rare phenomenon, with a reported incidence of only 0.0028 to 0.5%.4.5 A review of 50,000 patients in Austra lia and New Zealand by Paver et al found an incidence of 0.0028 %. 5 In another large review of 9,050 cases of basal cell carci noma at Mem orial Hospital in New York City, Contran found only nine cases of metastatic basa l cell carcinoma, for an incidence of 0.1%.6 Sm aller studies ENT-Ear, Nose & Throat Journal· July 2000 BASAL C ELL CA RCINOMA METASTATIC TO THE PAROTID : REPO RT O F A NEW CAS E AN D REVIEW O F THE LITERATURE have found sim ilar or only slightly higher incidences. "! Sex, race, age, and duration. Men are more predisposed to metastatic basa l cell carcinoma than women by a ratio of 2 to 1. 12 The most affected group are whites between the ages of20 and 60 years ." There are only five reported cases of metastatic basal cell carcinoma in black patients, and not all of these cases involved the head and neck." :" The median age of onset in pat ients with a primary tumor is 45 years, and the med ian interval between the appearance of the primary lesion and the onset of metastasis is 9 yea rs; in one case, the interval was 45 years.' ? Th e median life expectancy after a metastasis is ide ntifie d is only 8 months."
Riskfactors. There are several risk facto rs that appear to predi spose patients to metastatic basal ce ll carcin om a. Often , there is a history of a persisten t or rec urrent tumor of many years' duration. The lesion is typically refr actory to conve ntional for ms of therapy, and a history of radiation therapy for a large primary or repeatedly recurrent tum or has bee n noted. Th e de pth of tissue invasion and extension of the tu mor into adjacent anatomic structures can also increase the risk of metas tasis. 18.19 The location and size of the primary tumo r ap pea r to playa role in the development of metastases. Blewitt reviewed 38 cases of metastatic basal cell carc inoma and noted that the primary tumor was usually located on the sca lp or face." He also found that large tumors were an outstanding fea ture of metastatic basal cell carci no ma. His findi ng was suppo rted by a report of 12 cases of metastatic basal cell ca rci noma by Lo et ai, who noted that
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The unit is fully insulated and automatically sets itself to operating temperature. The ECM mirror warmer offers these advantages: reported that only about 9% of metastatic basal cell carcinomas originated in primary tumors that were smaller than 10cm 2 . 19 Finally, Sahl et al reported a45 % incidence of metastasis and/or death in patients whose primary tumors were larger than 10 em in diameter." Primary tumor morphology and histopathology. The primary tumor is usually quite exten sive, covering a large surface area with deep erosion into underlying tissue . Nevertheless, small primary tumors can also metastasize." Approximately 85% of metastatic basal cell carcinomas originate in primary tumors of the head and neck. In an exten sive review of 170 published cases of metastatic basal cell carcinoma, von Domarus and Stevens found that 67.6% of metastases originated in sites on the head and face, mostly on the midface. " Basal cell carcinomas in these regions have been noted to be more aggre ssive and destructive than lesions at other sites . 6 ,23 It has been postulated that the presence of embryonic fusion planes in the midface area results in more occult and distant spread, as well as more difficulty in surgical removal."
In general, the histopathology of basal cell carcinoma features small, uniform basaloid cells with scant cytoplasm and large , round, or elongated nuclei. Another characteristic finding is the palisading of nuclei at the tumor periphery. Several histologic varieties of basal cell carcinoma have been described, and it is possible to see a mixture of histologic types in a single lesion." :" The nodular subtype is the most common, and it usually remains localized to the primary site. It features the characteristic peripheral palisading and islands of tumor cells. Areas of central tumor nest necrosis or degeneration might be observed.
The second most common variety is the micro nodular subtype, which consists oftumorislands in small, rounded nodules . The morphology of these nodule s is similar to that of the larger nodular subtype. The keratotic variety is remarkable for its abrupt , central keratinization. The superficial subtype contains foci of tumor that extend from the epidermis adjacent to or into the papillary dermis. Peripheral palisading is well defined, and its contours are rounded and smooth. The morphea or sclerosing variant is an aggressive subtype, and local recurrences are common. This tumor consists of strands of closely arranged basaloid cells in dense , sclerotic stroma.
The infiltrative variety reveals tumor foci of varying sizes. These lesions have poorly defined peripheral palisading, with irregular, spiking contours. A higher incidence of incomplete excision and local recurrence has been seen in patients with this subtype, which is likely a result of the irregularity of the tumor." Metatypical or baso squamous carcinoma is a subtype that is characterized by varying degrees of squamous differentiation. This subtype also tend s to have a more aggressive biologic behavior, approaching that of a squamous cell carcinoma. A metastatic rate of up to 6% has been reported. "
Routes ofmetastasis. The primary routes of metastasi s of basal cell carcinomas are the lymphatic and hematogenous channels. Metastasis to regional lymph nodes has been noted by some authors to occur in as many as 70% of cases .28,29 Involvement of the parotid or submandibular glands as a result of metastasi s to intra-or periglandular lymph nodes has been reported to occur in patients with metastatic basal cell carcinoma that spreads from the head and face. 4 • 6 ,13,30.32 This is the most likely explanation for themetastasis in our patient. Common sites of hematogenous dissemination include the lung s and pleura, liver, bone, and skin." Other sites less frequently involved are the dura mater, pericardium, myocard ium, kidney, adrenal gland, thyroid , diaphragm, pancreas, and brain. Lung involvement has also been reported as a result of aspiration of tumor cells from invasive basal cell carcinoma of the nasal and oral cavities. "
Perineural invasion by basal cell carcinomas is rare, and cheek regions appeared to be the most common sites of basal cell carcinoma and perineural invasion; involvement of the facial and trigeminal nerves usually occurred first. Perineural invasion was observed most often in recurrent lesions, and more than 50 % of those patients had received previous radiation therapy. We now add an additional case of perineural involvement to those reports.
The underlying molecular mechanisms of tumor invasion and metastasis of basal cell carcinoma have yet to be elucidated. Farmer and Helwig have suggested that tumor metastasis is the result of immunologic alterations between the tumor and host. 35 Earlier experimental work has demonstrated the importance of the connective tissue stroma in the survival of tumor cells in human autotransplantation." Recent studies have examined the role of cellular adhesion molecules in tumor metastasis, but no correlation was noted in the expression or distr ibution of various cellular adhesion molecules by the different histologic subtypes of basal cell carcinoma." :" The pattern of integrins, a type of cellular adhesion molecule, expressed by basal cell carcinoma was simil ar to patterns expressed by the more aggressive malignant melanoma." In contrast, striking differences were noted in the expression of integrins on both squamous and basal cell carcinomas." It is difficult to draw definitive conclusions about the relationship between invasive potential and the differences in the expression of cellular adhesion molecules because of the phenotypical differences between tumor types.
Treatment. The therapeutic modalities used for metastatic basal cell carcinoma are surgery, radiation, chemotherapy, and a combination of the three . Treatment options are often dictated by the location and nature of the metastasis. Becau se of the paucity of cases, organized clinical trials to evaluate the efficacy of the various treatments are limited. Surgical management appears to provide the best long-term results ; Farmer and Helwig reported that postoperative survival in their study was as long as 9 years. " In the head and neck region, metastases are typic ally found in the intraparotid , periparoti d, and cer vical lymph nodes, A superficial or total parotidectomy and/o r a selective neck dissecti on is reco mmended, dep endin g on the extent and location of the tumor. Metastases to the bone , lung, and so ft tissues that are not amenable to sur gical resection can be treated with che motherapy . Currentl y, experience with chemotherapy and meta static basal ce ll carcinoma is limited to several case reports and small series. Pfeiffer et al have written an exce llent review of the literature on sys temic .cytotoxic therapy and basal ce ll carc inoma." Several agents have been reported to be succe ssful, alone or in co mbination with eac h other; they include cis-platinum, me thotrexa te, cyc lophosphamide, S-fluorouracil , bleom ycin , vincristine, and doxorubicin .? According to Pfeiffer et al, cisplatinum appears to be the most effective agent , as patient s who rece ived it had a median survival of 16 month s, co mpared with only 8 months for patients who were treated with other regi mens.
Radiation therapy is used alone or in co mbination with surgical resectio n to treat both primary and metastatic disease. It is ofte n used for extensi ve or inoperable lesions, Although long-term survival is unlikely, symptomatic reiief is ofte n attained . The rationale for postoperati ve radiotherapy of me tastatic basal cell carcinoma to the cervica l and paro tid regions paralle ls that of squamous ce ll carc inoma, but currently its role rem ains unclear.
Followup. Patien ts should be followed clo sely and undergo tumor surv eilla nce with a thoro ugh examination of the primary tum or site, as well as the regio nal lymphatic system. In addition, periodi c chest x-rays, liver function tests, and measurements of alka line phosphatase levels should be obtai ned to screen for distant metastases. RatHepatocyte DNARepair Assay Micronu cleus Test (Mice) Dominant lethalTest (Mice) long-term carcinogenicity studiesin miceand rats havebeen completed for ciprofloxacin. After daily oral doses of 750 mglkg (mice) and 250 mg/kg (rats) were administered for up to 2 years, there was noevidence thatciprofloxacin had any carcinogenic or tumorigenic effects in these species. Nolong termstudies ofCIPRO' HC OTIC suspensionhavebeen performed to evaluatecarcinogenic potential. Fertility studies performed in ratsat oraldoses of ciprofloxacin up to 100 mglkg/day revealed no evidence of impairment. This would beover 1000 times themaximum recommended clinical dose of ototopical ciprofloxaci n based upon body surface area, assuming total absorption of ciprofloxacinfromtheear of a patient treatedwith CIPRO' HCOTICtwiceperday. l ongterm studieshavenot been performed to evaluatethe carci nogenicpotent ialor theeffecton fert ilityoftopicalhydroco rtisone. Mutagenicitystudieswith hydrocortisonewerenegative. Pregnancy: Teratogenic Effects, Pregnancy Category C: Reproduction studies have been performedinrats and miceusingoral dosesof upto 100mglkg and IVdoses upto30mg/kg and haverevealednoevidence of harmtothefetusasaresult ofciprof loxacin. Inrabbits, ciprofloxacin (30and 100 mg lkg orally)producedgastrointestinaldisturbances resulting in mat ernal weight lossand an increasedincidenceof abortion, but noteratogenicitywasobservedat eitherdose. Aft er intravenous administration ofdosesup to 20mglkg. no maternaltoxi city was produced intherabbit, and no embryotoxicityorteratogenici tywas observed. Corticosteroidsaregenerally teratogenic inlaboratoryanimalswhenadmi nistered systemically at relatively low dosage level s. The more potentcorticosteroids have beenshown to be teratogenic after dermal applicationinlaboratoryanimal s. Ani mal reprod uction studies havenotbeen conductedwith CIPRO' HCOTIC. Noadequate and well controlled studieshave been performed in pregnantwomen. Caution should be exerci sedwhen CiPRO' HCOTiC isused by apregnant woman. Nur singMothers: Ciprofloxacin is excreted in human milk with systemic use. It is not known whether ci profloxacin is excreted in human milk following topical otic administration. Because of thepotential for seriousadversereactions in nursi ng infants,adecisionshould bemadewhetherto discontinuenursing or to discontinue thedrug, taking into account the importance of the drug to themother. Pediatric use: Thesafety and efficacy of CIPRO' HC OTIC have been established in pediatric pati ents 2yearsand older (131 patients) inadequate and well-controlled clinical trial s. Although no data are availableon patient s less than age 2 years. thereare no known safetyconcerns or differences inthediseaseprocess inthis population which would preclude use ofthis product in patients one year and older . See DOSAGE AND ADMINISTRATION.
A lc o n
ADVERSE REACTIONS
In Phase 3 clinical trials, a totalof 564pat ientsweretreatedwith CIPRO' HCOTIC. Adverse events withatleast remoterelat ionship to treatment included headache(1.2%)and pruritus (0.4%). Thefollowingtreatment-related adverse events wereeach reported inasingle patient: migraine, hypesthesia, paresthesia, fungal dermatitis, cough, rash, urt icaria, and alopecia. 
